Safety Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds

Wounds Clinical Trial

Official title:

A Single-Center, Prospective, Randomized Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01292122
• Other study ID #: 10-GDS-001-VCT
• Status: Terminated
• Phase: N/A
• First received: January 28, 2011
• Last updated: December 19, 2012
• Start date: June 2011
• Est. completion date: September 2012

Study information

• Verified date: December 2012
• Source: Organogenesis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of VCT-01 in split-thickness skin graft (STSG) donor site wounds and assess selected parameters of healing at the VCT-01-treated donor site.

Description:

An initial cohort of 5 subjects will be allocated to Group A. When all subjects enrolled in Group A have completed 14 days of post-treatment follow-up, results of donor site evaluations, histological analyses and reported adverse events will be reviewed by the Investigator and study Sponsor. If the data is suggestive of clinical benefit following treatment and absent any serious and/or unexpected adverse events, which are, in the opinion of the investigator, related to the treatment, the remaining subjects will be enrolled and randomized to Groups B, C or D.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: September 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Subject is at least 18 years of age but no more than 55 years of age.

2. Subject has a primary wound which requires treatment with a split-thickness skin graft; the graft cannot be harvested from a site from which a skin graft was previously obtained. If the primary wound is a result of a thermal or chemical burn, the total body surface area must be less than 15%.

3. Females of childbearing potential must have a documented negative urine pregnancy test and must agree to use highly effective contraceptives for 6 months post-treatment.

4. Subject has read, understood and signed a Health Research Ethics Board-approved Informed Consent Form.

5. Subject is able and willing to comply with study procedures and instructions.

Exclusion Criteria:

1. Female subjects who are pregnant or lactating.

2. Clinically significant disease or condition that may compromise graft take and/or donor site healing (e.g. the presence of a bleeding disorder, capillary fragility, venous or arterial disorder directly affecting the donor site to be treated, known or suspected systemic malignancies, human immunodeficiency virus infection, renal or liver disease, uncontrolled diabetes mellitus, thrombocytopenia, vasculitis, poor nutritional status).

3. Subjects who are currently receiving or have received within two months prior to treatment: systemic, inhaled or intranasal corticosteroids or immunosuppressant agents. Subjects receiving therapeutic doses of anticoagulants for pre-existing medical conditions (e.g. Plavix, Coumadin, Heparin, low molecular weight Heparin, non-steroidal anti-inflammatory drugs, herbal supplements), for whom a dose interruption from Screening through 2-Months post-treatment (pre-treatment / treatment / biopsy phase) is contraindicated, are excluded from the study.

4. Any disorder (psychiatric, alcohol or substance abuse [within 12 months of treatment], physical disability) that might interfere with obtaining informed consent or the subject's ability to comply with study or protocol requirements, as determined by the Investigator.

5. Subjects who have used any tobacco product within 3 months prior to treatment.

6. Subjects previously treated with Apligraf®, Dermagraft or any other cell-based product, including autologous tissue at the treatment site.

7. Subjects who have received an investigational drug, device or biological/bioactive treatment within 30 days prior to treatment (medical or dental).

8. Subjects, who in the opinion of the Investigator, for any reason other than those listed above, will not be able to complete the study per protocol.

9. Subjects, as determined by Screening immunology testing, that have specific antibodies to VCT-01 donor cell human leukocyte antigens.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Wounds

Intervention

Device:
• VCT-01
Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0

Locations

Country	Name	City	State
Canada	University of Alberta Hospital	Edmonton	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
Organogenesis

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Adverse Events and changes from Baseline Immunology at 1, 3, 6 and 12 Months	Frequency and severity of reported adverse events and changes in results of immunology testing at Months 1, 3, 6 and 12 post-treatment as compared to baseline testing	Up to 12 months post-treatment	Yes
Secondary	Healing parameter	Percentage area of questionable viability	Day 4 post-treatment	No
Secondary	Healing parameter	Percentage area of graft survival	Day 14 post-treatment	No
Secondary	Healing parameter	Histological and immunohistochemical analyses to examine cellular composition and tissue architecture.	Up to 10 days post-treatment	No
Secondary	Healing parameter	Microarray analysis to quantitatively measure molecular phenotypes expression.	Up to 10 days post-treatment	No
Secondary	Healing parameter	Short tandem repeat analysis for persistence of VCT-01	Up to 12 Months post-treatment	No